Evidence map›Paper›PMID 34158342›Full record

ArticleMolecular cancer therapeutics2021

Targeting TfR1 with the ch128.1/IgG1 Antibody Inhibits EBV-driven Lymphomagenesis in Immunosuppressed Mice Bearing EBV

Laura E Martínez, Tracy R Daniels-Wells, Yu Guo, Larry I Magpantay, Pierre V Candelaria, Manuel L Penichet, Otoniel Martínez-Maza, Marta Epeldegui

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular cancer therapeutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 10 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. The Role of Iron in Cancer Progression.Frontiers in oncology · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Laura E MartínezDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Tracy R Daniels-WellsDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0002-8277-9702
Yu GuoDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Larry I MagpantayDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Pierre V CandelariaDivision of Surgical Oncology, Department of Surgery, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.
Manuel L PenichetAIDS Institute, University of California Los Angeles, Los Angeles, California.
Otoniel Martínez-MazaDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California.ORCID 0000-0003-1364-0675
Marta EpeldeguiDepartment of Obstetrics and Gynecology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California. mepeldegui@mednet.ucla.edu.
California NanoSystems Institute · USUniversity of California, Los Angeles · US

Funding

Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KITCHEN, SCOTT G · 1991 to 2018
$39.9M
UCLA Tumor Immunology Training ProgramT32CA009120 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Steven M. Dubinett, MICHAEL A TEITELL · 1985 to 2026
$10.3M
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHLR01CA196266 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MARTINEZ-MAZA, OTONIEL, PENICHET, MANUEL L · 2016 to 2020
$3.4M
The Role of Follicular CD8+ T Cells in Pathogenesis of AIDS-NHL.R01CA228157 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EPELDEGUI, MARTA · 2019 to 2023
$1.8M
PDL1 expression on B cells: a potential marker of pre-tumor cells in AIDS-NHLR21CA220475 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI EPELDEGUI, MARTA · 2017 to 2018
$372k
NCI NIH HHS P30 CA016042NCI NIH HHS R01 CA196266NCI NIH HHS R01 CA228157NCI NIH HHS R21 CA220475NCI NIH HHS T32 CA009120NIAID NIH HHS P30 AI028697
6 · The paper itself

Abstract

Epstein-Barr virus (EBV) is a human gammaherpesvirus associated with the development of hematopoietic cancers of B-lymphocyte origin, including AIDS-related non-Hodgkin lymphoma (AIDS-NHL). Primary infection of B-cells with EBV results in their polyclonal activation and immortalization. The transferrin receptor 1 (TfR1), also known as CD71, is important for iron uptake and regulation of cellular proliferation. TfR1 is highly expressed in proliferating cells, including activated lymphocytes and malignant cells. We developed a mouse/human chimeric antibody targeting TfR1 (ch128.1/IgG1) that has previously shown significant antitumor activity in immunosuppressed mouse models bearing human malignant B-cells, including multiple myeloma and AIDS-NHL cells. In this article, we examined the effect of targeting TfR1 to inhibit EBV-driven activation and growth of human B-cells

Indexed as

AnimalsAntibodies, MonoclonalApoptosisB-LymphocytesCell ProliferationEpstein-Barr Virus InfectionsHerpesvirus 4, HumanHumansImmunoglobulin GLeukocytes, MononuclearLymphocyte ActivationLymphomaMiceMice, Inbred NODMice, SCIDReceptors, TransferrinAntibodies, MonoclonalImmunoglobulin GReceptors, Transferrin

Identifiers

PMID34158342
PMCPMC8419068
OpenAlexW3175640978

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.